QQQ   420.10 (+1.31%)
AAPL   166.80 (+1.09%)
MSFT   402.00 (+0.72%)
META   485.24 (+0.87%)
GOOGL   157.04 (+1.91%)
AMZN   177.62 (+1.71%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.37 (+1.86%)
NIO   4.03 (+6.05%)
BABA   70.87 (+2.61%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.79 (+2.83%)
GE   150.77 (+1.83%)
CGC   7.91 (-0.25%)
DIS   112.71 (+0.09%)
AMC   3.42 (+8.23%)
PFE   26.39 (+1.50%)
PYPL   63.29 (+1.57%)
XOM   121.06 (+0.98%)
QQQ   420.10 (+1.31%)
AAPL   166.80 (+1.09%)
MSFT   402.00 (+0.72%)
META   485.24 (+0.87%)
GOOGL   157.04 (+1.91%)
AMZN   177.62 (+1.71%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.37 (+1.86%)
NIO   4.03 (+6.05%)
BABA   70.87 (+2.61%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.79 (+2.83%)
GE   150.77 (+1.83%)
CGC   7.91 (-0.25%)
DIS   112.71 (+0.09%)
AMC   3.42 (+8.23%)
PFE   26.39 (+1.50%)
PYPL   63.29 (+1.57%)
XOM   121.06 (+0.98%)
QQQ   420.10 (+1.31%)
AAPL   166.80 (+1.09%)
MSFT   402.00 (+0.72%)
META   485.24 (+0.87%)
GOOGL   157.04 (+1.91%)
AMZN   177.62 (+1.71%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.37 (+1.86%)
NIO   4.03 (+6.05%)
BABA   70.87 (+2.61%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.79 (+2.83%)
GE   150.77 (+1.83%)
CGC   7.91 (-0.25%)
DIS   112.71 (+0.09%)
AMC   3.42 (+8.23%)
PFE   26.39 (+1.50%)
PYPL   63.29 (+1.57%)
XOM   121.06 (+0.98%)
QQQ   420.10 (+1.31%)
AAPL   166.80 (+1.09%)
MSFT   402.00 (+0.72%)
META   485.24 (+0.87%)
GOOGL   157.04 (+1.91%)
AMZN   177.62 (+1.71%)
TSLA   142.27 (-3.25%)
NVDA   799.14 (+4.87%)
AMD   149.37 (+1.86%)
NIO   4.03 (+6.05%)
BABA   70.87 (+2.61%)
T   16.33 (-1.09%)
F   12.88 (+6.10%)
MU   109.79 (+2.83%)
GE   150.77 (+1.83%)
CGC   7.91 (-0.25%)
DIS   112.71 (+0.09%)
AMC   3.42 (+8.23%)
PFE   26.39 (+1.50%)
PYPL   63.29 (+1.57%)
XOM   121.06 (+0.98%)
NASDAQ:REGN

Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis

$907.55
+10.73 (+1.20%)
(As of 03:09 PM ET)
Today's Range
$897.45
$908.67
50-Day Range
$893.99
$993.35
52-Week Range
$684.80
$998.33
Volume
179,733 shs
Average Volume
490,883 shs
Market Capitalization
$99.61 billion
P/E Ratio
26.12
Dividend Yield
N/A
Price Target
$976.41

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
7.9% Upside
$976.41 Price Target
Short Interest
Healthy
1.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.69
Upright™ Environmental Score
News Sentiment
0.42mentions of Regeneron Pharmaceuticals in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$13.12 M Sold Last Quarter
Proj. Earnings Growth
4.02%
From $38.80 to $40.36 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.68 out of 5 stars

Medical Sector

239th out of 907 stocks

Pharmaceutical Preparations Industry

96th out of 428 stocks

REGN stock logo

About Regeneron Pharmaceuticals Stock (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Stock Price History

REGN Stock News Headlines

This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Cantor Fitzgerald Reaffirms Their Hold Rating on Regeneron (REGN)
This Apple-like Innovator is Revolutionizing Healthcare
AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.
Regeneron Pharmaceuticals (NASDAQ:REGN) Trading Down 2.6%
See More Headlines
Receive REGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneron Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/02/2024
Today
4/22/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:REGN
CUSIP
75886F10
Employees
13,450
Year Founded
1988

Price Target and Rating

Average Stock Price Target
$976.41
High Stock Price Target
$1,189.00
Low Stock Price Target
$720.00
Potential Upside/Downside
+8.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
20 Analysts

Profitability

Net Income
$3.95 billion
Pretax Margin
32.01%

Debt

Sales & Book Value

Annual Sales
$13.12 billion
Cash Flow
$43.26 per share
Book Value
$236.63 per share

Miscellaneous

Free Float
100,070,000
Market Cap
$98.43 billion
Optionable
Optionable
Beta
0.11

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Should I Buy Regeneron Pharmaceuticals Stock? REGN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Regeneron Pharmaceuticals, Inc.:

  • Regeneron Pharmaceuticals has a diverse product portfolio, including innovative medicines like EYLEA and Dupixent, which have shown significant success in treating various diseases.
  • The company's ongoing research and development efforts demonstrate a commitment to advancing healthcare solutions and potentially introducing new breakthrough treatments.
  • Regeneron's collaboration with other pharmaceutical companies and research institutions enhances its capabilities for developing cutting-edge therapies and expanding its market reach.
  • Recent positive regulatory approvals and clinical trial results have boosted investor confidence in the company's future growth prospects and revenue potential.
  • Despite market fluctuations, Regeneron's stock price has shown resilience and maintained a relatively stable performance, offering investors a sense of security and potential long-term returns.

Cons

Investors should be bearish about investing in Regeneron Pharmaceuticals, Inc. for these reasons:

  • Regeneron Pharmaceuticals faces intense competition in the biopharmaceutical industry, which could impact its market share and profitability over time.
  • The company's heavy reliance on a few key products, such as EYLEA and Dupixent, for a significant portion of its revenue poses a risk in case of unexpected market changes or regulatory challenges.
  • Fluctuations in research and development outcomes or delays in product launches could affect investor sentiment and lead to short-term volatility in the stock price.
  • Regeneron's exposure to regulatory changes, pricing pressures, and intellectual property disputes within the healthcare sector may create uncertainties for investors regarding the company's future financial performance.
  • Investing in biotechnology companies like Regeneron Pharmaceuticals involves inherent risks related to clinical trial failures, patent expirations, and market unpredictability, which could impact investment returns.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Regeneron Pharmaceuticals pros and cons to contact@marketbeat.com.

REGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Regeneron Pharmaceuticals stock right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 15 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" REGN shares.
View REGN analyst ratings
or view top-rated stocks.

What is Regeneron Pharmaceuticals' stock price target for 2024?

20 Wall Street research analysts have issued 12 month price objectives for Regeneron Pharmaceuticals' shares. Their REGN share price targets range from $720.00 to $1,189.00. On average, they expect the company's share price to reach $976.41 in the next year. This suggests a possible upside of 7.9% from the stock's current price.
View analysts price targets for REGN
or view top-rated stocks among Wall Street analysts.

How have REGN shares performed in 2024?

Regeneron Pharmaceuticals' stock was trading at $878.29 at the start of the year. Since then, REGN shares have increased by 3.0% and is now trading at $904.85.
View the best growth stocks for 2024 here
.

When is Regeneron Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our REGN earnings forecast
.

How can I listen to Regeneron Pharmaceuticals' earnings call?

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its earnings results on Friday, February, 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts' consensus estimates of $10.73 by $1.13. The biopharmaceutical company had revenue of $3.43 billion for the quarter, compared to analysts' expectations of $3.29 billion. Regeneron Pharmaceuticals had a net margin of 30.14% and a trailing twelve-month return on equity of 17.61%. Regeneron Pharmaceuticals's quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the business posted $10.96 EPS.
Read the conference call transcript
.

What is Leonard S. Schleifer's approval rating as Regeneron Pharmaceuticals' CEO?

423 employees have rated Regeneron Pharmaceuticals Chief Executive Officer Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and Salesforce (CRM).

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Global Assets Advisory LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.29%), Perpetual Ltd (0.08%), Raymond James & Associates (0.06%), Allspring Global Investments Holdings LLC (0.05%) and Atwood & Palmer Inc. (0.04%). Insiders that own company stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Bonnie L Bassler, Christine A Poon, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Joseph L Goldstein, Leonard S Schleifer, Marc Tessier-Lavigne, Marion Mccourt, Michael S Brown, N Anthony Coles, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Plew Daniel P Van, Robert E Landry and Robert E Landry.
View institutional ownership trends
.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Regeneron Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, OSMR Holdings, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.
Read More
This page (NASDAQ:REGN) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners